The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer by Ofer N. Gofrit et al.
March 2016 | Volume 6 | Article 431
Original research
published: 15 March 2016
doi: 10.3389/fonc.2016.00043
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Fabio Grizzi, 
Humanitas Clinical and Research 
Center, Italy
Reviewed by: 
Simona Di Francesco, 
People’s University Nicholas 
Copernicus, Italy 
Sanja Stifter, 
University of Rijeka, Croatia
*Correspondence:
Ofer N. Gofrit  
ogofrit@gmail.com
Specialty section: 
This article was submitted to 
Genitourinary Oncology, 
a section of the journal 
Frontiers in Oncology
Received: 02 July 2015
Accepted: 12 February 2016
Published: 15 March 2016
Citation: 
Gofrit ON, Yutkin V, Shapiro A, 
Pizov G, Zorn KC, Hidas G, 
Gielchinsky I, Duvdevani M, 
Landau EH and Pode D (2016) The 
Response of Variant Histology 
Bladder Cancer to Intravesical 
Immunotherapy Compared to 
Conventional Cancer. 
Front. Oncol. 6:43. 
doi: 10.3389/fonc.2016.00043
The response of Variant histology 
Bladder cancer to intravesical 
immunotherapy compared to 
conventional cancer
Ofer N. Gofrit1* , Vladimir Yutkin1 , Amos Shapiro1 , Galina Pizov2 , Kevin C. Zorn3 ,  
Guy Hidas1 , Ilan Gielchinsky1 , Mordechai Duvdevani1,2 , Ezekiel H. Landau1 and  
Dov Pode1
1 Department of Urology, Hadassah Hebrew University Medical Center, Jerusalem, Israel, 2 Department of Pathology, 
Hadassah Hebrew University Medical Center, Jerusalem, Israel, 3 Section of Urology, Department of Surgery, Montreal, 
QC, Canada
Background: High-grade urothelial carcinomas (UCs) often show foci of variant differ-
entiation. There is limited information in the literature about the response of these variant 
urothelial tumors to immunotherapy with bacillus Calmette–Guerin (BCG). We compared 
the response, to treatment with BCG, of UC containing glandular, squamous, nested, 
and micropapillary types of differentiation to response of conventional non-muscle inva-
sive high-grade UC.
Methods: A total of 100 patients were diagnosed with variant histology urothelial cancer 
between June 1995 and December 2013. Forty-one patients with Ta or T1, confirmed 
by second look biopsies, received immunotherapy with BCG. Fourteen patients in this 
group were diagnosed with micropapillary differentiation, 13 patients with squamous dif-
ferentiation, 9 patients with glandular differentiation, and 7 patients with nested variants. 
The control group included 140 patients with conventional high-grade UC. Both groups 
have been treated and followed similarly.
Findings: Patients with variant tumors had similar clinical features to patients with 
conventional disease, including age, male to female ratio, stage, the presence of Tis, 
and median follow-up. Patients with variant tumors had a significantly worse prognosis 
compared to patients with conventional high-grade UC, including 5-year recurrence-free 
survival (63.5 Vs. 71.5%, p = 0.05), 5-year progression (≥T2)-free survival (60 Vs. 82.5%, 
p =  0.002), 5-year disease-specific survival (73 Vs. 92.5%, p =  0.0004), and overall 
survival (66 Vs. 89.5%, 0.05).
interpretation: A patient with variant bladder cancer treated with intravesical immuno-
therapy has a 27% chance of dying from this disease within 5 years compared to 7.5% 
chance for a patient with conventional high-grade UC.
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inTrODUcTiOn
The tendency of the urothelium to undergo various types of 
metaplasia is well-known. Foci of differentiation toward different 
epithelial types are frequently encountered in urothelial tumors. 
Histological variant urothelial carcinoma (UC) diagnosed in up to 
20% of the transurethral tumor excisional biopsies and squamous 
differentiation is the most common type (1). Other frequently diag-
nosed variant UC included glandular, micropapillary, and the nested 
variants (2). These tumors often show clinically aggressive behavior 
with muscle invasion and extravesical extension (3–5). Variant 
tumors are frequently associated with poor prognosis (1, 2, 6). Some 
authors suggest that variant tumors are more aggressive compared 
to conventional tumors (6), although many authors maintain that 
the prognosis after radical cystectomy is similar in both groups.
When a patient with variant histology UC presents with 
muscle invasive tumor, the decision to perform radical surgery 
is relatively easy. When there is no detrusor invasion there is a 
dilemma. There are only a few reports on response of patients 
with variant tumors to immunotherapy with bacillus Calmette–
Guerin (BCG) (7). The micropapillary pattern is an exception 
with several studies addressing this point in the literature, how-
ever, with inconsistent results. Kamat et  al. treated 27 patients 
with micropapillary tumors with BCG (8). Only 19% were free of 
tumor after 30 months of follow-up. As such, they concluded that 
BCG is not effective against UC with micropapillary differentia-
tion and suggested that radical cystectomy is the treatment for 
all these patients. Willis et al. arrived at a similar conclusion (9). 
In their study, the prognosis of patients with T1 micropapillary 
tumors treated with cystectomy was compared to patients treated 
with immunotherapy. The 5-year disease-specific survival was 
100% for 26 patients who underwent immediate cystectomy com-
pared to only 60% for the patients receiving primary intravesical 
immunotherapy (p = 0.006). Spaliviero et al., on the other hand, 
using similar methodology, did not find a difference in disease-
specific mortality between patients treated with early cystectomy 
and those given primary intravesical immunotherapy.
Unfortunately, adequate information is not available on other 
tumor variants. In a small study, a combined series of tumor 
variants encouraging results for immunotherapy were reported 
(7). Patients with variant tumors had higher progression rate but 
similar disease-specific survival in comparison to patients with 
conventional high-grade tumors treated with immunotherapy.
In the current study, an extended group of patients with non-
muscle invasive variant UCs was compared to a group of patients 
with conventional UC treated with intravesical immunotherapy. 
Both groups were treated and followed using the same protocol.
MaTerials anD MeThODs
Patient Population
The study is based on review of the hospital database that holds 
information on 1210 consecutive patients who underwent tran-
surethral resection of bladder urothelial tumors between June 
1995 and December 2013. Pathological staging was performed 
according to the TNM system and histological grading was 
performed according to the ISUP/WHO classification by a single 
uropathologist (Galina Pizov). Patients with sarcomatoid or small 
cell carcinoma were not included in the study due to their poor 
prognosis and unique features. The study was approved by the 
IRB (number 207-31.10.08).
Treatment Protocol
Patients with high-grade UC without muscularis propria invasion 
were subjected to the “second look” biopsies and were considered 
suitable for treatment with BCG if there was no invasion into 
the muscularis propria. The immunotherapy protocol included 
an induction course of six weekly intravesical instillations of 
OncoTICE BCG in 50 cc of normal saline, initiated 10–20 days 
following the second surgery. Maintenance therapy included two to 
three instillations every 3 months for 1 year with following proce-
dure every 6 months for additional 2 years. Radical cystectomy was 
offered to patients with disease progression to stage T2 or tumors 
resistant to immunotherapy or recurrent high-grade, T1 or Tis.
Follow-up protocol included cystoscopy and cytology every 
3 months for 2 years and every 6 months for another 3 years with 
a liberal policy of biopsies from any suspicious lesion. Upper tract 
surveillance (intravenous pyelography and more recently CT 
urography) was performed on initial diagnosis and then annually 
for 3 years.
statistical analysis
The outcome of patients with variant tumors receiving BCG 
immunotherapy was compared to the outcome of patients with 
conventional high-grade UC treated with BCG during the same 
time period. Continuous variables were compared using t-test 
and categorical variables with the Fisher’s exact test. Survival 
analysis was done using the Kaplan–Meier and log-rank meth-
ods. A p-value <0.05 was considered significant and all tests were 
two-tailed. Statistical analysis was done using the JMP software 
(SAS Cary, NC, USA).
resUlTs
A total of 100 patients with variant bladder tumors were registered. 
These included 36 patients with micropapillary differentiation, 23 
with squamous, 19 with glandular differentiation, and 22 with 
nested variant UC. There were no patients with lymphoepithelial 
or plasmacytoid variants. In 10 patients, more than one type of 
differentiation was noted.
Forty-one patients with non-muscle invasive disease con-
firmed by second look biopsies were treated with intravesical 
BCG. All other patients were referred for cystectomy. All patients 
had high-grade tumors. The clinical features of patients treated 
with BCG are presented in Table 1. The most common variant 
described was the micropapillary type. Patients with the four 
variants showed common clinical features (Table 1).
The 2- and 5-year survival rates of the four variants are shown 
in Table  2 and Figure  1 and are quite similar to each other. 
Patients with the glandular variant had a tendency toward better 
prognosis while patients with the micropapillary and squamous 
variants exhibited worse prognosis.
Comparison of patients with variant tumors and patients with 
conventional high grade UC treated with BCG is presented in 
FigUre 1 | Kaplan–Meier curves of the various variant types. (a) Recurrence-free survival, (B) progression (≥T2)-free survival, (c) disease-specific survival, 
and (D) overall survival.
TaBle 2 | Two- and five-year survival rates according to type of variant tumor.
Variant Overall survival
2 years/5 years
Disease-specific survival
2 years/5 years
Progression-free survivala
2 years/5 years
recurrence-free survival
2 years/5 years
Micropapillary 75%/0% 69.8%/69.8% 69.8%/69.8% 61.1%/50.9%
Squamous 92.3%/79.1% 65.3%/43.5% 65.2%/43.5% 66.1%/44.1%
Nested 100%/0.80% 100%/75% 83.3%/50% 71.4%/23.8%
Glandular 100%/83.3% 100%/100% 100%/100% 100%/66.7%
Totala 92.5%/66% 85.6%/73.4% 85.6%/60% 72.3%/63.5%
aTo stage ≥T2.
TaBle 1 | Features of the patients with various tumor variants.
Variant number of patients Mean age (sD) % Males stages a/1 (%) cis (%) Median follow-up (months)
Micropapillary 14 75.9 ± 8.8 93 4/10 (40) 7 (50) 32
Squamous 13 68.1 ± 12.6 92 0/13 (0) 6 (46) 53
Nested 7 68 ± 12.7 71 2/5 (40) 2 (29) 110
Glandular 9 75.2 ± 5.6 89 4/5 (80) 3 (33) 46
Totala 41 71.9 ± 10.8 88 10/31 (24) 19 (46) 43
aTwo patients had more than one type.
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TaBle 3 | comparisons of the features of patients with conventional and variant tumors.
  number of patients Mean age (sD) % Males stages a/1 (%) cis (%) Median follow-up (months)
Variant 41 71.9 ± 10.8 88 10/31 (24) 19 (46) 43
Conventional 140 69.9 ± 10.4 86 39/101 (27.8) 72 (51) 54
p Value – 0.24 1 0.84 0.6 0.39
TaBle 4 | comparison of the prognosis of patients with conventional and variant tumors.
Variant Overall survival
2 years/5 years
Disease-specific survival
2 years/5 years
Progression-free survival
2 years/5 years
recurrence-free survival
2 years/5 years
Variant 92.5%/66% 85.6%/73.4% 85.6%/60% 72.3%/63.5%
Conventional 94.6%/89.5% 97%/92.5% 91.2%/82.5% 79.2%/71.5%
p Value 0.05 0.0004 0.002 0.05
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FigUre 2 | Kaplan–Meier curves comparing variant tumors to conventional high-grade tumors treated with immunotherapy. (a) Recurrence-free 
survival (p = 0.05), (B) progression (to stage >T2)-free survival (p = 0.002), (c) disease-specific survival (p = 0.0004), and (D) overall survival (p = 0.05).
Table  3. Both groups were similar in age, male to female ratio, 
stages a/1 ratio, and the presence of Tis. Median follow-up was also 
similar. The recurrence-free survival, progression-free survival, 
disease-specific, and overall survival rates were all significantly 
worse for patients with variant histology tumors (Table 4; Figure 2).
DiscUssiOn
In this study, 43 variant bladder tumors without invasion to 
muscularis propria founded in 41 patients and treated with 
intravesical BCG were studied. All four variants included in the 
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investigation collectively demonstrate similar clinical behavior 
(Figure 1; Table 2).
The prognosis for patients with UC with squamous and 
micropapillary patterns was similar (Table  2). The 5-year 
disease-specific survival of patients with the micropapillary was 
70%, which is comparable to the rate reported by Spaliviero et al. 
(75%) (10), and better than the outcomes observed by Willis et al. 
(60%) (9). Unfortunately, there is no reference in the literature for 
comparison of other variant tumors. The 5-year disease-specific 
survival of all the tumor variants combined was 73.4%, which is 
also similar to the 75% reported by Spaliviero et al., for patients 
with micropapillary differentiation (10).
Patients with variant tumors had similar clinical features, 
including age distribution, male to female ratio, stage Ta/T1 ratio, 
and the presence of Tis to patients with conventional high-grade 
tumors (Table 3).
As shown in Table  4 and Figure  2, patients with variant 
tumors had significantly worse prognosis compared to patients 
with conventional tumors in all four parameters examined 
(recurrence-free, progression-free, disease-specific, and overall 
survival rates). The fact that all the parameters were significantly 
worse strengthens the conclusion that these patients have poorer 
prognosis, especially concerning the difference in disease-specific 
survival. The 2- and 5-year disease-specific survival rates were 
97 and 92.5% for conventional and 85.6 and 73.4% for variant 
tumors (p = 0.0004). This means that patients with variant tumors 
have not only a lower response rate to BCG reflected by the higher 
recurrence and progression rates but also lower chance for suc-
cessful salvage after progression.
This study is a continuation of a previous report (7), which 
 demonstrated more recurrences and shorter progression-free survivals 
in patients with variant tumors but similar disease-specific survival. 
The current study contained double number of patients and showed 
that disease-specific and overall survivals are also worse for patients 
with variant tumors.
The study is limited by the small number of patients and also by 
being single institutional and retrospective. The combined analysis of 
several variant tumors together is another limiting factor. Combining 
several variants is a common methodology (3, 11, 12), and as shown 
here, the clinical features and prognosis of the four common variants 
are quite similar (Tables 1 and 2).
cOnclUsiOn
The management of patients with non-muscle invasive variant 
bladder tumors with intravesical immunotherapy with BCG is risky 
even when confirmation of diagnosis with second look biopsies and 
meticulous follow-up are employed. The progression rate of these 
patients to muscle invasive disease is high (40% at 5 years compared 
to 17.5% in conventional high-grade tumors). Furthermore, the 
chance of successful salvage, after progression is lower compared 
to conventional high-grade tumors. A patient with a variant tumor 
treated with intravesical immunotherapy has a 27% chance of dying 
from this disease within 5 years compared to 7.5% chance for a patient 
with conventional high-grade carcinomas. As such, patients with 
variant tumors should be advised of this adverse clinical course and 
considerations for cystectomy strongly recommended.
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